INTRODUCTION {#h0.0}
============

Bacterial cells often exist as members of multicellular communities known as biofilms, which are commonly formed by both commensal and pathogenic bacteria ([@B1], [@B2]). Bacteria within a biofilm are encased within a complex extracellular matrix ([@B3]) that often provides protection against toxic substances ([@B4], [@B5]) and desiccation ([@B6]) and facilitates nutrient exchange ([@B7]). Biofilms are difficult to control due to their intrinsic antibiotic tolerance ([@B8]). Therapeutic intervention targeting bacterial attachment and the subsequent steps that lead to biofilm formation could hold promise in treating a variety of bacterial infections. Understanding how these bacteria orchestrate the transition from a motile, free-living lifestyle to a sessile, multicellular biofilm is a major goal of recent research.

Cyclic diguanylate monophosphate (c-di-GMP) is a nucleotide second messenger ([@B9], [@B10]) that plays a critical role in the regulation of bacterial attachment and biofilm formation in diverse bacteria. Since its discovery over 25 years ago ([@B11]), c-di-GMP has been implicated in controlling processes intimately associated with biofilm formation such as polysaccharide biosynthesis ([@B12], [@B13]), production and transport of biofilm matrix components ([@B14], [@B15]), oxygen-dependent regulation ([@B16]), and motility ([@B17]). In addition, c-di-GMP can also control virulence ([@B18], [@B19]) and morphological development ([@B20], [@B21]). Intracellular c-di-GMP levels are perceived through several varieties of c-di-GMP-responsive receptors, enzyme allosteric sites, transcription factors, and riboswitches ([@B19], [@B22][@B23][@B25]). Elevated levels of c-di-GMP typically favor the sessile state, resulting in increased attachment and biofilm formation, whereas lower levels of c-di-GMP favor the motile, planktonic state and the downregulation of attachment ([@B10]).

The c-di-GMP concentration within a cell is controlled by the opposing activities of diguanylate cyclases (DGCs) and phosphodiesterases (PDEs), which possess synthetic and degradative activities, respectively ([@B10], [@B26]). DGCs are characterized by the GGDEF catalytic motif ([@B21]), and PDEs are characterized by either an EAL ([@B27], [@B28]) or HD-GYP catalytic motif ([@B29]). Proteins with both GGDEF and EAL domains are common, but in many examples, one of the domains is catalytically inactive ([@B30], [@B31]). There are few examples of enzymes that are known to have both DGC and PDE activities ([@B32][@B33][@B35]), and their *in vivo* regulation and activity are poorly understood ([@B36][@B37][@B38]).

*Agrobacterium tumefaciens* is a facultative plant pathogen that causes the neoplastic disease called crown gall via cross-kingdom horizontal gene transfer and integration of plasmid-derived tumorigenic DNA into the plant genome ([@B39][@B40][@B41]). *A. tumefaciens* forms biofilms on both biotic and abiotic surfaces ([@B42], [@B43]), with attachment to the plant surface as a required component of plant transformation. Attachment to a range of surfaces is dependent upon the unipolar polysaccharide (UPP) adhesin ([@B44], [@B45]) with additional influence from cellulose ([@B46], [@B47]). Regulation of *A. tumefaciens* attachment is controlled by multiple integrated regulatory pathways ([@B48]), several of which play a role in modulating intracellular c-di-GMP levels.

Shortly after its original discovery, the presence of c-di-GMP was detected in *A. tumefaciens*, and its role in the regulation of cellulose synthesis was described ([@B13]). This regulation was recently attributed, at least in part, to a DGC in *A. tumefaciens* ([@B49], [@B50]) that is homologous to the well-studied PleD GGDEF protein from *Caulobacter crescentus*. The levels of c-di-GMP have also been shown to directly regulate attachment, with elevated c-di-GMP concentrations driven by overexpression of the *A. tumefaciens* PleD leading to increased levels of UPP production, cellulose synthesis, and biofilm formation ([@B50]). Despite these observations, little is known about how c-di-GMP signaling is integrated into the overall regulatory network for controlling attachment and biofilm formation in *A. tumefaciens.*

In the search for regulatory candidates, a transposon mutagenesis screen was performed for mutants that mimicked the elevated UPP production phenotype of a PleD-overexpressing strain ([@B50]). Several classes of transposon mutations were described, including the *visNR* locus, encoding the master motility regulators in *A. tumefaciens*, now known to inhibit c-di-GMP synthesis through two DGC proteins that do not include PleD. Two other intriguing mutant classes included a putative pteridine reductase (Atu1130, designated here as PruA) and a dual GGDEF-EAL protein (Atu3495, now designated DcpA \[[d]{.ul}iguanylate [c]{.ul}yclase/[p]{.ul}hosphodiesterase [A]{.ul}\]). Transposon mutations in either *dcpA* or *pruA* led to increased staining with the polysaccharide-reactive dye Congo red (reporting on UPP and cellulose production) and elevated attachment and biofilm formation ([@B50]), suggesting that these genes are negative regulators of *A. tumefaciens* surface interactions. It was hypothesized that a loss of DcpA PDE function might lead to increased UPP and cellulose production through elevated levels of c-di-GMP.

In this study, the PDE activity of DcpA is shown to be necessary for the negative regulation of attachment. However, DcpA can also act as a DGC, implicating DcpA as a dual-function DGC-PDE protein. The primary state of DcpA activity in *A. tumefaciens* is regulated via a complex control pathway that involves the production of a low-molecular-weight metabolite known as a pterin, a class of redox-reactive enzymatic prosthetic groups, by a putative pteridine reductase (PruA). This control of DcpA influences UPP and cellulose production, attachment, and biofilm formation of *A. tumefaciens*. The pterin produced by PruA requires a putative pterin-binding protein PruR, encoded immediately upstream of DcpA, to influence DcpA activity, establishing a mechanism by which pterin-dependent signaling modulates the balance between motile to sessile growth modes for *A. tumefaciens*.

RESULTS {#h1}
=======

Genetic and phenotypic evidence for DcpA phosphodiesterase and diguanylate cyclase activity. {#s1.1}
--------------------------------------------------------------------------------------------

Our previous studies suggested that the Atu3495 gene product (now designated DcpA), which contains highly conserved GGDEF and EAL domains, acts as a phosphodiesterase (PDE) in wild-type *A. tumefaciens* based on several surface attachment-associated phenotypes of a *dcpA* in-frame deletion mutant ([@B50]). The DcpA coding sequence is 1,935 bp and is located on the *A. tumefaciens* C58 linear chromosome, 8 bp downstream of a predicted open reading frame coding for the conserved hypothetical protein Atu3496. Hence, these two genes are likely to form an operon ([Fig. 1A](#fig1){ref-type="fig"}). Atu3496 and its potential relationship to DcpA will be described below. Upstream of the Atu3496 gene and separated by 181 bp is the Atu3497 gene, which encodes a conserved hypothetical protein with no recognized domains.

![Complementation of increased biofilm formation in the *A. tumefaciens* dcpA mutant requires an intact DcpA EAL catalytic motif. (A) Diagram of PruR-DcpA genetic locus. Atu3497 is a conserved hypothetical protein with no annotated domains. (B) Protein topology of DcpA. Protein domains predicted by the BLAST database (NCBI) are shown. Domains are drawn to scale. TM, transmembrane; DGC, diguanylate cyclase; PDE, phosphodiesterase. (C) *A. tumefaciens* quantitative biofilm formation on PVC coverslips after 48 h of static growth at 28°C. Adherent biomass was quantified by staining with crystal violet (CV). CV absorbance was quantified by absorbance at 600 nm (*A*~600~). In parallel, the optical density at 600 nm (OD~600~) of planktonic culture was determined. CV absorbance was normalized to culture growth by calculating the *A*~600~/OD~600~ ratio. IPTG (400 µM) was added to all strains. The wild-type (WT) strain, Δ*dcpA* mutant with no plasmid inserted (-), and Δ*dcpA* mutant strain with *P~lac~*-*dcpA* derivatives are shown. A wild-type copy of *dcpA* provided on a plasmid expressed from the *lacZ* promoter (*P~lac~*-*dcpA*; DGC^+^PDE^+^) was introduced into a Δ*dcpA* mutant. The *P~lac~*-*dcpA* derivatives include a DcpA variant containing catalytic site GGDEF→GGDAF mutation (DGC−) and a DcpA variant containing catalytic site EAL→AAL mutation (PDE−). Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 standard deviation (SD).](mbo0031523790001){#fig1}

The N terminus of DcpA contains a predicted periplasmic region of approximately 140 amino acid (aa)  residues flanked by two transmembrane domains ([Fig. 1B](#fig1){ref-type="fig"}). It is possible that this periplasmic segment plays a sensory function, but the region is not homologous to any known protein domains. A predicted DGC domain (residues 226 to 381) lies carboxy terminal to the periplasmic domain. This domain contains a GGDEF motif and other conserved residues needed for proper enzymatic activity of canonical DGC proteins, such as those involved in GTP and metal binding (see [Fig. S1A](#figS1){ref-type="supplementary-material"} in the supplemental material) ([@B23], [@B51]). Notably, DcpA lacks a conserved RXXD I-site motif, which is normally involved in negative allosteric feedback of c-di-GMP synthesis ([@B23]). The PDE domain of DcpA (residues 400 to 672) is composed of a canonical EAL catalytic motif and other essential residues necessary for metal coordination ([Fig. S1B](#figS1){ref-type="supplementary-material"}). In summary, DcpA has all the necessary residues consistent with enzymatically active DGC and PDE domains and is named *dcpA* (for [d]{.ul}iguanylate [c]{.ul}yclase/[p]{.ul}hosphodiesterase [A]{.ul}).

In order to delve further into the mechanistic basis for the aforementioned phenotypes and to genetically test DcpA's role as a PDE, a targeted mutation (E431A) was constructed to change the EAL catalytic motif to AAL. In parallel and in combination with the EAL mutation, the GGDEF catalytic motif of DcpA was mutated to GGDAF (E308A). These mutations have been reported to enzymatically inactivate PDE domains and DGC domains, respectively ([@B26], [@B27], [@B50], [@B52]).

A wild-type copy of *dcpA* provided on a plasmid expressed from the *lacZ* promoter (*P~lac~*-*dcpA*; DGC+PDE+) was introduced into a Δ*dcpA* mutant, and when it was induced with isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside (IPTG), it diminished biofilm formation of the Δ*dcpA* mutant ([Fig. 1C](#fig1){ref-type="fig"}, P value of \<0.05 by paired *t* test) and Congo red staining, reflecting polysaccharide levels, to near wild-type (WT) levels (see [Fig. S2A](#figS2){ref-type="supplementary-material"} in the supplemental material). Decreased biofilm formation was responsive to increasing levels of IPTG ([Fig. S2B](#figS2){ref-type="supplementary-material"}). Mutating the GGDEF catalytic motif (E308A) had no effect on the ability of *dcpA* to complement the null mutation ([Fig. 1C](#fig1){ref-type="fig"}, P value of \<0.05 by paired *t* test compared to the value for the WT). However, mutation of the EAL motif in the PDE domain (E431A) alone abolished the ability of *dcpA* to complement the mutant biofilm phenotype back to WT levels, and this plasmid in fact stimulated biofilm formation approximately 10-fold greater than that observed in the Δ*dcpA* mutant ([Fig. 1C](#fig1){ref-type="fig"}, P value of \<0.05 by paired *t* test). This elevated level of biofilm formation is due to a functional GGDEF motif, as the plasmid-borne *dcpA* double mutant (E308A E431A) did not elevate biofilm levels above the Δ*dcpA* mutant ([Fig. 1C](#fig1){ref-type="fig"}). The phenotypes of the PDE disabled *dcpA* variant were not multicopy effects, as the mutation introduced into the native copy of *dcpA* resulted in the same phenotypes as the plasmid-borne allele ([Fig. S2A](#figS2){ref-type="supplementary-material"} and data not shown). Direct measurement of c-di-GMP in whole-cell extracts revealed that the Δ*dcpA* mutant tended to be slightly elevated, but these values were not statistically different from wild-type *A. tumefaciens* ([Fig. S3A](#figS3){ref-type="supplementary-material"}, P value of 0.09 by paired *t* test).

The impact of the *dcpA* mutations on biofilm formation, Congo red staining, and c-di-GMP levels in the wild-type strain was determined. Providing the plasmid-borne *dcpA* gene in the wild-type background depressed levels of biofilm formation ([Fig. 2A](#fig2){ref-type="fig"}, P value of \<0.05 by paired *t* test compared to the WT value). Slight, nonsignificant decreases in Congo red staining and c-di-GMP concentrations (*P* value of 0.12 by paired *t* test compared to the WT value) were also observed ([Fig. 2B and C](#fig2){ref-type="fig"}). Introduction of the *dcpA* GGDEF motif (E308A) mutant plasmid (DGC^−^PDE^+^) resulted in a similar decrease (*P* value of 0.05 by paired *t* test compared to the WT value), but expression of the EAL mutant (E431A) resulted in a striking increase (*P* value of \<0.05 by paired *t* test compared to the WT value) in the above phenotypes ([Fig. 2A to C](#fig2){ref-type="fig"}), suggesting that DcpA exhibits DGC enzymatic activity when PDE activity is abrogated. The concentration of c-di-GMP in the strain expressing the *dcpA* double mutant (E308A E431A) plasmid was not different from the plasmid-free strain (*P* value of 0.29 by paired *t* test compared to the WT value).

![Genetic analysis reveals DGC activity of DcpA. (A) Biofilms grown for 48 h on PVC coverslips were quantified as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. A wild-type strain with no plasmid inserted (-) is shown. The error bars show 1 standard deviation (SD). (B) Congo red colony phenotypes of *A. tumefaciens* strains after 48 h of growth at 28°C (vertically aligned with strain designations in panel A). (C) Quantification of intracellular levels of c-di-GMP in the indicated *A. tumefaciens* or *E. coli* strains. A DcpA variant containing catalytic site GGDEF→GGDAF mutation (DGC−) and a DcpA variant containing catalytic site EAL→AAL mutation (PDE−) were tested. c-di-GMP was measured by LC-MS/MS as described in [Text S1](#textS1){ref-type="supplementary-material"} in the supplemental material*.* Values are results of two (*A. tumefaciens*) or three (*E. coli*) independent biological replicates consisting of three technical replicates each. The error bars show 1 SD.](mbo0031523790002){#fig2}

DcpA exhibits DGC activity in a heterologous host. {#s1.2}
--------------------------------------------------

Production of c-di-GMP is often controlled by a variety of upstream regulatory pathways, specific to the bacterial species in which they have evolved ([@B9], [@B10]). We hypothesized that *A. tumefaciens* might express regulatory proteins that modulate the DGC and PDE activity of DcpA. To examine enzymatic activity in a heterologous host lacking any *A. tumefaciens*-specific regulatory machinery, wild-type and mutant variants of DcpA were expressed from a multicopy plasmid in *Escherichia coli* DH5α. *E. coli* DH5α has a low basal level of c-di-GMP, and we have previously used it as an assay strain to show that several *A. tumefaciens* DGCs can elevate intracellular c-di-GMP levels significantly above the low endogenous *E. coli* background ([@B50]).

Unlike wild-type *A. tumefaciens*, expression of plasmid-borne wild-type *dcpA* in *E. coli* increased intracellular c-di-GMP concentrations by more than 2 orders of magnitude compared to the plasmid-less background ([Fig. 2C](#fig2){ref-type="fig"}, P value of \<0.05 by paired *t* test). This increase in c-di-GMP was entirely dependent on the DGC activity of DcpA, as the GGDEF (E308A) mutation did not increase or decrease c-di-GMP levels compared to the wild type (*P* value of 0.26 by paired *t* test). This plasmid derivative is not generally dysfunctional, as it was able to successfully complement the *A. tumefaciens* Δ*dcpA* mutant for its presumptive PDE activity ([Fig. 1A](#fig1){ref-type="fig"}). The DGC activity of the EAL (E431A) mutant was similar to that of wild-type DcpA, indicating that the DGC activity of DcpA is functionally independent of PDE activity when the protein is expressed in *E. coli*. This is consistent with our finding in *A. tumefaciens* in which the PDE^−^ mutant exhibited strong DGC activity ([Fig. 1A](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"}). Expression of the double mutant (E308A E431A) had no effect on c-di-GMP levels. Overall, these data suggest that DcpA acts as a potent DGC when expressed in *E. coli* and that DcpA DGC activity is likely to be regulated by factors or conditions native to *A. tumefaciens*.

A putative pteridine reductase negatively regulates biofilm formation and UPP production in *A. tumefaciens*. {#s1.3}
-------------------------------------------------------------------------------------------------------------

We had identified additional candidate UPP and attachment regulators in our prior transposon mutant screen for UPP dysregulation ([@B50]) and hypothesized that some of these might consolidate into common control pathways. Of the four classes of candidate regulators, transposon mutations in Atu1130 exhibited the highest level of biofilm formation when disrupted ([@B50]). As detailed below, Atu1130 and DcpA are functionally linked in their control over UPP production and surface attachment in general.

The Atu1130 gene is on the circular chromosome, and it is expressed divergently from an outer membrane protein homolog designated *aopB* (Atu1131). The 3′ end of the Atu1130 coding sequence overlaps by 4 bp with the downstream gene homologous to the UvrC UV repair exinuclease protein (Atu1129), suggesting that these genes are translationally coupled. The Atu1130 gene encodes a 262-aa gene product that shares significant sequence similarity with pteridine reductase proteins, a subclass of the short-chain dehydrogenase/reductase protein family ([@B53], [@B54]). The annotated pteridine reductase domain extends from positions 14 to 247 and is the only recognized domain of the Atu1130 protein. Due to these characteristics, Atu1130 was renamed PruA ([p]{.ul}teridine reductase [r]{.ul}egulator of [U]{.ul}PP [A]{.ul}). Pteridine reductases catalyze the NADPH-dependent reduction of metabolites derived from GTP, known as pterins, to their biologically active forms. The most well-known pterin-containing molecules are folates, while other pterin compounds, such as the molybdopterin cofactor, biopterins, and monapterins, function as enzymatic prosthetic groups that drive redox catalysis ([@B55][@B56][@B58]). The pteridine reductase family is characterized by a conserved YXXXK catalytic motif that is necessary for enzymatic function ([@B53], [@B59], [@B60]). PruA contains the canonical YXXXK motif (see [Fig. S4A](#figS4){ref-type="supplementary-material"} in the supplemental material) and exhibits predicted secondary and tertiary structural homology with well-characterized pteridine reductases such as PTR1 from *Leishmania donovani* ([Fig. S4D](#figS4){ref-type="supplementary-material"}).

An in-frame deletion of *pruA* that retains the potential translational coupling with *uvrC* results in an approximately fivefold elevation of biofilm formation compared to the wild type ([Fig. 3A](#fig3){ref-type="fig"}, P value of \<0.05 by paired *t* test). As predicted by elevated biofilm levels, a *pruA* mutant also had slight, but statistically higher levels of c-di-GMP than the wild type did (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material, *P* value of \<0.05 by paired *t* test). The Δ*pruA* mutant also formed dark red colonies on Congo red-containing medium ([Fig. 3B](#fig3){ref-type="fig"}), indicative of elevated levels of cellulose and UPP. The elevated levels of biofilm formation and Congo red staining were returned to normal levels ([Fig. 3A and B](#fig3){ref-type="fig"}) by ectopic expression of a plasmid-borne copy of *pruA* (*P~lac~-pruA*), confirming that the mutant phenotypes are not due to polarity on *uvrC*.

![Enzymatic activity of PruA required for control of attachment. (A) Biofilms grown on PVC coverslips for 48 h were quantified as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. A wild-type strain with no plasmid inserted (-) and the *pruA* mutant strain with no plasmid inserted (-) are indicated. The error bars show 1 SD. (B) Congo red colony phenotypes of the indicated *A. tumefaciens* strains. The bacteria were grown for 48 h at 28°C. (C) Unipolar polysaccharide (UPP) production (red) visualized by staining with Alexa Fluor 594-labeled wheat germ agglutinin (afWGA). Exponential-phase planktonic cultures were incubated with afWGA (10 µg/ml) and spotted (1 µl) onto 1% agarose pad. Bacteria were viewed at a magnification of ×100 on a Nikon E800 epifluorescence microscope (excitation, 510 to 560 nm; emission, \>610 nm). The images shown are overlays of phase-contrast and fluorescence microscopy images. The images were exposed for 40 and 400 ms for phase-contrast and fluorescence microscopy, respectively. IPTG (400 µM) was added to each culture. Bars, 5 µm.](mbo0031523790003){#fig3}

To observe UPP production directly, cells were stained using wheat germ agglutinin (WGA) conjugated to the Alexa Fluor 594 fluorescent label (af-WGA). WGA specifically binds to *N*-acetylglucosamine-containing polysaccharides and specifically labels the site of UPP production in *A. tumefaciens* ([@B50], [@B61]). UPP production is tightly dependent on surface attachment in wild-type *A. tumefaciens* ([@B62]), and little to no WGA staining was observed for planktonically grown cultures ([Fig. 3C](#fig3){ref-type="fig"}). In contrast, the Δ*pruA* mutant exhibited abundant UPP staining and high levels of cellular aggregation, also consistent with cellulose production ([Fig. 3C](#fig3){ref-type="fig"}). UPP staining was concentrated in the large cell aggregates, but it was also visible on single cells. As UPP production is normally not observed in planktonically grown cells ([@B50], [@B62]), synthesis of the adhesin is thus uncoupled from surface attachment in the Δ*pruA* mutant, consistent with other regulatory mutants identified in our initial screen such as *visN* and *visR* ([@B50]). The plasmid-borne *pruA* gene complements the mutant phenotypes back to wild-type levels. These observations suggest that PruA is an important regulatory player in the pathway controlling the *A. tumefaciens* motile-to-sessile transition.

PruA enzymatic activity required for function. {#s1.4}
----------------------------------------------

To test whether the enzymatic activity of PruA was required for negative regulation of attachment phenotypes, a site-directed mutation (Y163A) that altered the tyrosine residue in the presumptive active site (YXXXK) of PruA to an alanine was generated. In other systems, these mutations have been shown to abolish pteridine reductase activity but not affect protein stability ([@B60]). A plasmid expressing wild-type *pruA* can diminish biofilm formation and Congo red phenotypes in a Δ*pruA* mutant ([Fig. 3A and B](#fig3){ref-type="fig"}). In contrast, the PruA Y163A mutation abolished the ability of this plasmid to complement, exhibiting biofilm levels and Congo red staining indistinguishable from those of the mutant without the plasmid ([Fig. 3A and B](#fig3){ref-type="fig"}, *P* value of 0.34 by paired *t* test). The Y163A mutation was also introduced into the native genomic context of *pruA* by allelic replacement, and this mutant was similar to the Δ*pruA* deletion strain with respect to all measured phenotypes, including biofilm formation (see [Fig. S5](#figS5){ref-type="supplementary-material"} in the supplemental material) and Congo red staining (data not shown). PruA enzymatic activity thus appears to inhibit surface attachment processes, including UPP production in *A. tumefaciens*.

PruA orthologs from other bacteria can rescue the *A. tumefaciens pruA* mutant. {#s1.5}
-------------------------------------------------------------------------------

PruA orthologs are observed in several related members of the *Rhizobiales* order and *Alphaproteobacteria* class, including *Sinorhizobium meliloti*, *Caulobacter crescentus*, *Ruegeria pomeroyi*, and *Brucella abortus*, with all homologs exhibiting approximately 40% amino acid identity or higher. Each of the PruA orthologs possesses a canonical YXXXK motif (see [Fig. S4A](#figS4){ref-type="supplementary-material"} in the supplemental material), suggesting a conserved enzymatic function. When expressed from *P~lac~* on a plasmid, all of these homologs drove the Δ*pruA* biofilm phenotype and Congo red staining toward wild-type levels ([Fig. S4B and C](#figS4){ref-type="supplementary-material"}). The closest *E. coli* homolog to PruA is known as FolM (26% identity to PruA), an experimentally validated pteridine reductase. FolM functions as a dihydropterin reductase, reducing dihydromonapterin (H~2~-MPt) to tetrahydromonapterin (H~4~-MPt) ([@B58]). Strikingly, ectopic expression of *folM* in *A. tumefaciens* also partially reverses the biofilm and Congo red phenotypes of the Δ*pruA* mutant ([Fig. S4B and C](#figS4){ref-type="supplementary-material"}).

PruA is required for production of a novel pterin. {#s1.6}
--------------------------------------------------

In order to evaluate the activity of PruA, we examined the intracellular pterin profiles in fractionated preparations from *A. tumefaciens* using high-performance liquid chromatography (HPLC) with fluorescence detection. All analyses were performed on oxidized extracts, as pterin derivatives in their oxidized state are strongly fluorescent. This technique is highly sensitive for oxidized pterin species, but its use precludes the determination of the reduction state of the pterin. This analysis showed the presence of three major pterin-containing peaks ([Fig. 4A](#fig4){ref-type="fig"}). The peak that eluted at 11.7 min corresponds to pterin ([Fig. 4B](#fig4){ref-type="fig"}), a major degradation product of tetrahydrofolate, commonly found in cell extracts ([@B63]). The peak at 3.8 min is likely a folate biosynthetic intermediate containing a phosphate group, and although this compound appeared to decrease in the cells lacking PruA, the significance of this is not yet clear. The peak eluting at 12.5 min had a characteristic pterin absorbance spectrum and was strikingly absent from the Δ*pruA* and *pruA* Y163A mutants but was present when the Δ*pruA* mutant was complemented with the *P~lac~-pruA* plasmid.

![PruA enzymatic activity required for pterin synthesis. (A) HPLC traces of pterin extracts from the indicated *A. tumefaciens* strains. Lyophilized cells were resuspended, and pterins were extracted, purified, and analyzed by HPLC as described in Materials and Methods. (B) Pterin chemical structures (ring positions shown).](mbo0031523790004){#fig4}

Since the species eluting at 12.5 min did not match any known pterin based on retention time, the peak was collected and analyzed further by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The unknown pterin had a (M+H)^+^ of 268 *m*/*z* and (M-H)^−^ of 266 *m*/*z*, corresponding to a molecular mass of 267 Da, consistent with the addition of a methyl group to neopterin or monapterin, which differ only in stereochemistry at the 2′ position ([Fig. 4B](#fig4){ref-type="fig"}). Collision-induced dissociation (CID) of the (M-H)^−^ precursor ion gave rise to a pterin fragment at 162 *m/z*, indicating that the methyl group is not on the pterin portion of the molecule and must be present on the side chain to generate an O-methylated neopterin or monapterin derivative. FolM from *E. coli* reduces 7,8-dihydromonapterin (H~2~MPt) to 5,6,7,8-tetrahydromonapterin (H~4~MPt) but has no activity with 7,8-dihydroneopterin ([@B58]). Given the similarity of PruA and FolM, it seemed likely that the PruA substrate is 7,8-dihydromonapterin and that the methylated pterin compound we identified in *A. tumefaciens* is a methylated monapterin rather than neopterin. We synthesized 6-methoxymethylpterin (lacking the full side chain of the monapterin) and analyzed the compound by LC-MS/MS. The MS/MS data obtained from this compound were very different from the data obtained from the unknown pterin isolated from *A. tumefaciens* (data not shown), indicating that the methyl group was not likely at the 1′ position, and further analysis led us to propose O-methylation at the 2′ position. We therefore synthesized 2′-*O*-methylmonapterin, and HPLC and LC-MS/MS analyses revealed that it had the same retention time and MS/MS spectrum as the *A. tumefaciens* pterin ([Fig. S7B and S7C](#figS7 figS7){ref-type="supplementary-material"}). The unknown oxidized pterin present in *A. tumefaciens* is therefore 2′-*O*-methylmonapterin.

*A. tumefaciens* PruA was purified as a hexahistidinyl-tagged PruA protein (His6-PruA) from *E. coli*. The purified protein was tested for enzymatic activity, monitoring oxidation of NADPH, and was found to reduce H~2~MPt (specific activity, 0.726 ± 0.039 µmol min^−1^ mg^−1^), but it had no activity with dihydroneopterin, dihydrofolate, or other oxidized pterins. Thus, PruA does function as predicted for a pteridine reductase. Taken together, our results indicate that PruA can generate H~4~MPt from H~2~HPt but that another cellular activity in *A. tumefaciens* must convert this to 2′-*O*-methyltetrahydromonapterin (2′-OMet-H~4~MPt). One or both of these pterins regulate DcpA activity and attachment.

Regulatory connection between PruA and DcpA. {#s1.7}
--------------------------------------------

In our initial transposon mutant screen ([@B50]), *pruA* and *dcpA* mutants exhibited similar phenotypes, and thus, we hypothesized that they might function together. To test the hypothesis that *pruA* and *dcpA* are part of the same regulatory pathway, plasmid-borne copies of either *pruA* or *dcpA* were introduced independently into the Δ*dcpA* and Δ*pruA* mutant backgrounds. Expressing *pruA* in a *dcpA* mutant did not change its phenotype compared to the untransformed *dcpA* mutant (data not shown). In contrast, expressing *dcpA* in a *pruA* background (deleted for cellulose \[Cel−\] to reduce excessive clumping) resulted in an approximately twofold increase above the already elevated biofilm phenotype of the Δ*pruA* mutant alone ([Fig. 5A](#fig5){ref-type="fig"}, P value of \<0.05 by paired *t* test). This increased biofilm formation was accompanied by increased cell aggregation and elevated UPP staining ([Fig. 5B](#fig5){ref-type="fig"}) and an increase of more than 2 orders of magnitude in intracellular c-di-GMP concentrations compared to the Δ*pruA* strain ([Fig. 5A](#fig5){ref-type="fig"}, P value of \<0.05 by paired *t* test). Introducing the *P~lac~*-*dcpA* plasmid into the chromosomal *pruA* catalytic site mutant (Y163A) increased biofilm formation similar to that observed in the *ΔpruA* background (see [Fig. S5](#figS5){ref-type="supplementary-material"} in the supplemental material). Thus, in contrast to the PDE activity of DcpA that predominates in wild-type *A. tumefaciens*, DcpA acts as a strong DGC in the absence of an enzymatically active copy of *pruA*, analogous to its activity when expressed in *E. coli.*

![Regulatory connections between PruA and DcpA. (A) Biofilms grown for 48 h on PVC coverslips (gray bars) were quantified as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. The error bars show 1 SD. c-di-GMP levels were also quantified (black bars). Strains were grown to stationary phase, nucleotides were extracted, and c-di-GMP was measured as described in Materials and Methods. A DcpA variant with catalytic site GGDEF→GGDAF mutation (DGC−), DcpA variant containing catalytic site EAL-\>AAL mutation (PDE−), and mutant with no plasmid inserted (-) were used. The Δ*cel* background was utilized to reduce excess clumping. Values are results of three (biofilm) or two (c-di-GMP) independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. (B) UPP production visualized by staining with afWGA, as described in the legend to [Fig. 3C](#fig3){ref-type="fig"}. IPTG (400 µM) was added to each culture. Bars, 5 µm. (C) Adherent biomass grown for 48 h was quantified as described above for panel A, with IPTG omitted.](mbo0031523790005){#fig5}

The plasmid carrying the GGDEF mutant allele (E308A) of *dcpA* was introduced into the Δ*pruA* background, and it did not stimulate elevated biofilm formation or increase c-di-GMP levels ([Fig. 5A](#fig5){ref-type="fig"}, P value of \>0.05 by paired *t* test). The elevation of biofilm and c-di-GMP levels was still strongly stimulated by introduction of the plasmid-borne EAL mutant (E431A) of *dcpA* in the Δ*pruA* background, suggesting again that DcpA DGC activity is functionally independent of an enzymatically active PDE domain. Plasmid-borne expression of the GGDEF-EAL double mutant (E308A E431A) had no effect on the Δ*pruA* phenotypes. It seemed likely that the Δ*pruA* phenotypes might be DcpA dependent, and a Δ*pruA* Δ*dcpA* double mutant was found to diminish biofilm levels below that of the Δ*pruA* single mutant to that of the Δ*dcpA* mutant ([Fig. 5C](#fig5){ref-type="fig"}, P value of \<0.05 by paired *t* test). Thus, the *dcpA* mutation is epistatic to *pruA* and is downstream in the regulatory pathway. The very strong *pruA* mutant phenotypes are also likely due to the combined effect of a decrease in DcpA PDE activityand sustained or stimulated DcpA DGC activity.

PruA-dependent regulation of DcpA requires a putative pterin-binding protein. {#s1.8}
-----------------------------------------------------------------------------

Despite our observations for PruA and DcpA, it was not clear how PruA-dependent pterin production could control DcpA. As mentioned above, *dcpA* is immediately preceded by Atu3496 in a putative operon ([Fig. 1A](#fig1){ref-type="fig"}) ([@B50]). In fact, several transposon insertion mutations were identified in the Atu3496 gene during the initial mutant screen. Atu3496 is a 169-aa protein, the majority of which (positions 34 to 172) shows modest but significant similarity to an oxidoreductase molybdopterin-binding domain (pfam00174, BLAST E value of 3.14 × 10^−8^, specific match to *E. coli* YedY, HHPred E value of 1.5 × 10^−31^). These domains are generally utilized for molybdopterin cofactor binding, through conjugation at a conserved cysteine residue that is required for the proper function of redox enzymes such as sulfite oxidases ([@B55]). This cysteine residue is absent in the Atu3496 gene, and several conserved residues are divergent, suggesting that it may not bind molybdopterin specifically. There are several homologous proteins in other *Alphaproteobacteria* that also lack this conserved cysteine (see [Fig. S6A](#figS6){ref-type="supplementary-material"} in the supplemental material). We hypothesized that this domain in Atu3496 might instead provide response to the pterin derivative produced by PruA. We tentatively designated the gene *pruR* ([p]{.ul}teridine reductase [r]{.ul}egulator of [U]{.ul}PP [r]{.ul}eceptor).

An in-frame deletion in *pruR* was generated, with care taken not to disrupt the start site or ribosome-binding site of *dcpA*. Deletion of *pruR* resulted in an approximately 3.5-fold increase in biofilm formation compared to the wild type ([Fig. 6A](#fig6){ref-type="fig"}, P value of \<0.05 by paired *t* test), increased af-WGA labeling ([Fig. 6B](#fig6){ref-type="fig"}), and elevated Congo red staining (data not shown), indicating that PruR negatively regulates attachment processes in *A. tumefaciens*. Ectopic expression of a plasmid-borne *pruR* gene reduced the biofilm levels of a Δ*pruR* mutant only slightly (*P* value of \<0.05 by paired *t* test), whereas providing expression of a plasmid with both *pruR* and *dcpA* in their normal tandem configuration reduced biofilm formation very strongly to below wild-type levels ([Fig. 6A](#fig6){ref-type="fig"}, P value of \<0.05 by paired *t* test). The strong suppressive effect on the *pruR* phenotype observed with the *P~lac~*-*pruR-dcpA* tandem expression plasmid was abolished in a Δ*pruA* Δ*pruR* double mutant (see [Fig. S6B](#figS6){ref-type="supplementary-material"} in the supplemental material). The requirement for this dual-gene plasmid suggests a strong *cis* association and perhaps a cotranslational interaction. We are confident that the Δ*pruR* mutation does not disrupt the downstream *dcpA*, and this is further supported in that providing a plasmid-borne *dcpA* alone in this mutant stimulates biofilm formation rather than returning the elevated levels of *pruR* closer to the wild-type levels, the opposite effect one would predict for correcting a *dcpA* deficiency (see below). These data suggest that *pruR* and *pruA* might act in concert to regulate DcpA activity

![PruR negatively regulates biofilm formation. (A) Biofilms grown for 48 h on PVC coverslips were quantified as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. A Δ*pruR* mutant with no plasmid inserted is indicated (-). The error bars show 1 SD. (B) UPP production visualized by staining with afWGA, as described in the legend to [Fig. 3C](#fig3){ref-type="fig"}. Bars, 5 µm. (C) Adherent biomass grown for 48 h was quantified as described above for panel A, with IPTG omitted. The Δ*cel* background was utilized to reduce excess clumping. (D) Quantification of c-di-GMP levels in the indicated *E. coli* strains. The *E. coli* strains were grown to late exponential phase, and nucleotides were extracted and quantified as described in [Text S1](#textS1){ref-type="supplementary-material"} in the supplemental material. Values are results of two independent biological replicates each with three technical replicates. The error bars show 1 SD.](mbo0031523790006){#fig6}

PruR is required to maintain the dominant PDE activity of DcpA. {#s1.9}
---------------------------------------------------------------

We predicted that PruR would regulate the dual enzymatic activities of DcpA, and thus, a switch in DcpA enzymatic activity might be observed in a *pruR* mutant similar to *pruA* mutants. To test this, the *P~lac~*-*dcpA* plasmid was expressed in the *A. tumefaciens* Δ*pruR* mutant (also mutated for the cellulose biosynthetic genes to prevent aggregation) and assayed for biofilm formation. As observed before, a Δ*pruR* mutant exhibited higher biofilm levels than the wild type did ([Fig. 6C](#fig6){ref-type="fig"}, P value of \<0.05 by paired *t* test). Expression of the plasmid-borne *dcpA* increased biofilm formation approximately fourfold above the Δ*pruR* mutant ([Fig. 6C](#fig6){ref-type="fig"}, P value of \<0.05 by paired *t* test). The *dcpA*-mediated increase in biofilm formation was abrogated in the DcpA (E308A) GGDEF catalytic site mutant ([Fig. 6C](#fig6){ref-type="fig"}). However, plasmid-borne expression of the DcpA (E431A) EAL catalytic site mutant stimulated biofilm formation equivalent to the wild-type gene, indicating again that the DGC activity was retained in the PDE mutant ([Fig. 6C](#fig6){ref-type="fig"}). Furthermore, introduction of the *P~lac~*-*pruR*-*dcpA* plasmid into *E. coli* did not increase c-di-GMP levels, in contrast to the dramatic increases observed with the *P~lac~-dcpA* plasmid ([Fig. 6D](#fig6){ref-type="fig"}). Overall, these data suggest that PruR, like PruA, controls the enzymatic activity of DcpA. PruR and PruA by themselves are both necessary but not sufficient for proper regulation of DcpA, as DcpA functions as a PDE only in the presence of both PruA and PruR.

DISCUSSION {#h2}
==========

In this study, we confirm and expand our initial report ([@B50]) on *dcpA* (Atu3495) in *A. tumefaciens*. We demonstrate that DcpA PDE activity, and specifically the EAL domain, is essential for the negative regulation of UPP adhesin production, cellulose synthesis, and biofilm formation, through its impact on c-di-GMP levels that regulate production of these polysaccharides and other aspects of the motile-to-sessile transition. We also describe, through the use of site-specific mutagenesis, the ability of DcpA to exhibit *in vivo* DGC activity, and that the DGC and PDE activities are independent of each other. Our findings reveal that the DcpA activity is controlled through a novel, pterin-dependent regulatory mechanism.

A dual-function diguanylate cyclase-phosphodiesterase in *A. tumefaciens*. {#s2.1}
--------------------------------------------------------------------------

Demonstration of both DGC and PDE enzymatic activities from the same protein is not typical, as a large percentage of proteins with both GGDEF and EAL domains exhibit only one of the two functionalities ([@B30], [@B31]). For those examples of proteins with both activities, the overarching regulatory networks that control them are often unclear, and *in vivo* data are scarce. We find here that the enzymatic activity of PruA (Atu1130), is responsible for the negative control of attachment phenotypes through the PDE activity of DcpA, as manifested through the function of the PruR protein (Atu3496).

There are a limited number of well-studied dual-function proteins with both PDE and DGC activity. Arguably the best-known DGC-PDE protein is ScrC from *Vibrio parahaemolyticus*, which positively regulates swarming and negatively regulates capsular polysaccharide (CPS) production ([@B37]). ScrC is a transmembrane protein with a periplasmic domain, and its PDE activity requires ScrB, a periplasmic solute-binding protein homolog, and ScrA, homologous to pyridoxal-dependent-enzymes ([@B36]). ScrA generates an extracellular signal (S-signal), and together with ScrB, it promotes the PDE activity of ScrC. In the absence of ScrA and ScrB, the DGC activity of ScrC dominates. Thus, for both ScrC and DcpA, c-di-GMP turnover is controlled by two upstream regulatory partners (ScrA and ScrB in *V. parahaemolyticus* and PruA and PruR in *A. tumefaciens*). In each case, one regulatory partner is required to synthesize a small molecule, S-signal by ScrA and a pterin by PruA. Another recently described dual-function DGC-PDE is BphG1 of *Rhodobacter sphaeroides*, consisting of an N-terminal photosensory module coupled to a C-terminal output module containing GGDEF and EAL domains ([@B34]). Purified full-length BphG1 demonstrates PDE activity *in vitro*, but ablation of the EAL domain results in strong DGC activity. It remains unclear whether similar cleavage of the EAL domain occurs *in vivo*, and BphG1 DGC activity has not been observed in a native background. In contrast, for DcpA, we observe both DGC and PDE activity *in vivo*, and these activities have clear cellular phenotypes linked to DcpA output.

Pterin synthesis and DcpA regulation. {#s2.2}
-------------------------------------

It is now clear that the enzymatic activity of PruA is required for DcpA PDE activity and that PruA directs the formation of 5,6,7,8-tetrahydromonapterin (H~4~MPt). Extracts from *A. tumefaciens* reveal PruA-dependent production of the novel monapterin 2′-OMet-H~4~MPt, and thus, the H~4~MPt that is the direct product of PruA activity is likely to be a substrate for methylation by an as-yet-unidentified enzyme ([Fig. 7](#fig7){ref-type="fig"}; see [Fig. S7A](#figS7){ref-type="supplementary-material"} in the supplemental material). Since pterins readily undergo oxidation and degradation upon isolation from cells, we do not observe the tetrahydro product in *A. tumefaciens* extracts but instead observe the oxidized form of the pterin, 2′-OMet-MPt ([Fig. 4A](#fig4){ref-type="fig"}).

![Model of pterin-dependent DcpA regulation. A tentative model for DcpA regulation is shown. The model is based on the findings reported here, with details provided in the text. Solid black arrows are enzymatic reactions, dashed arrows are regulatory interactions, and the squiggly arrow is a speculative environmental influence on the putative PruR-pterin (Pt) complex. Red text indicates essential genes in *A. tumefaciens*. IM, inner membrane; OM, outer membrane; GTs, glycosyl transferases; MoPT, molybdopterin; P-ase, phosphatase.](mbo0031523790007){#fig7}

In well-studied systems, monapterin biosynthesis branches from folate metabolism ([@B58]), and we predict that this is similar in *A. tumefaciens* ([Fig. 7](#fig7){ref-type="fig"}). Both folate and monapterin are derived from GTP through the common intermediate 2,3-dihydroneopterin triphosphate (H~2~NPt-P~3~) by a GTP cyclohydrolase, encoded by *folE* in *E. coli*, and homologous to Atu1749 in *A. tumefaciens* ([@B64]). The well-studied molybdopterin cofactor is synthesized via a different pathway that also utilizes GTP as an intermediate ([@B65]). Analogous to the *E. coli* pathway for monapterin biosynthesis, the likely pathway in *A. tumefaciens* would share several key enzymes with folate biosynthesis, acting on either a neopterin for folate or a monapterin ([Fig. 7](#fig7){ref-type="fig"}). H~2~MPt formed by this pathway could then be reduced to H~4~-MPt. In *A. tumefaciens*, all of the enzymes predicted to be required prior to the PruA-dependent reaction are essential for growth ([Fig. 7](#fig7){ref-type="fig"}, red Atu genes), even in rich medium ([@B66]), thus explaining why no other transposon mutants with *pruA*-type phenotypes were obtained for this pathway. This also suggests that in *A. tumefaciens*, folate is essential for growth, but monapterin is not.

PruR-pterin interactions. {#s2.3}
-------------------------

PruR is required for the PruA-dependent control of the enzymatic activity of DcpA by promoting its PDE activity. Although PruR is annotated as a molybdopterin-binding protein, it is degenerate and most importantly missing the key cysteine ligand for molybdopterin ([@B67]). As it is clear that PruA drives H~4~MPt synthesis, the simplest model is that PruR can respond to a monapterin. Cells with active PruA produce 2′-OMet-H~4~MPt, presumably derived from methylation of H~4~MPt, but no mutants with the *pruA* phenotype were obtained for any annotated methyltransferase. Therefore, it is possible that H~4~MPt produced by PruA is in fact the active molecule for PruR-dependent control or that the methyltransferase gene is another essential gene.

A relatively simple model is that a PruA-dependent pterin interacts with PruR, perhaps by forming a complex. Such a PruR-pterin complex could directly or indirectly interact with DcpA to promote its PDE activity ([Fig. 7](#fig7){ref-type="fig"}). More-complex models might also be envisioned, such as a mechanism by which the monapterin species limits the action of an inhibitor of PruR. Such a mechanism would be consistent with the observation that PruR effectively switches DcpA from its DGC dominant state in *E. coli*, a host that does not produce the novel monapterin we have detected in *A. tumefaciens*.

Since the PDE activity predominates under standard culture conditions in wild-type *A. tumefaciens*, it is possible that the PDE domain, when enzymatically active, exerts a negative regulation on the DGC domain. In ScrC of *V. parahaemolyticus*, the GGDEF catalytic motif is required for its PDE activity ([@B38]), but in contrast, the DcpA PDE activity appears to remain functional in GGDEF catalytic site mutants. Alternatively, both domains may be active, but the PDE activity greatly exceeds the DGC activity, leading to predominant c-di-GMP inactivation, and thus inhibition of attachment functions such as UPP and cellulose.

Pterin-dependent regulation. {#s2.4}
----------------------------

It is not obvious why or how monapterins would control DcpA activity. The simplest explanation is that the intracellular concentration of a specific monapterin(s) directly modulates DcpA, probably through interactions with PruR. The monapterin pathway derives from GTP and folate synthesis, and thus, the concentration of these compounds could reflect the overall levels of GTP. Alternatively, the monapterin could function as several other GTP derivatives such as c-di-GMP and ppGpp ([@B10], [@B68], [@B69]) directly as a second messenger.

It is also plausible that monapterin might function as a sensor of the cytoplasmic redox state through association with PruR and perhaps DcpA. PAS domains containing heme cofactors have been shown to modulate PDE activity through reversible binding of oxygen ([@B70], [@B71]). Redox sensing by flavin cofactors can regulate the enzymatic activity of a DGC protein in *Acetobacter xylinum* ([@B72]), and it is possible that pterins could operate in a similar capacity ([@B58]). Reduced pterins are known to act as robust antioxidants in mammalian cells ([@B73]), and high levels of oxidized neopterin are associated with increased concentrations of reactive oxygen species (ROS) ([@B74]). Additionally, several pterins are involved in regulating a redox-sensitive transcription factor in mammalian cells ([@B75], [@B76]). Oxygen availability has been postulated to play an important role during biofilm formation in *A. tumefaciens* ([@B43]), and biofilms often generate oxygen gradients ([@B77]). Sensing oxygen or changes in intracellular redox balance during the transition from the motile to sessile state could be mediated in part through monapterin control of DcpA.

The mechanism by which PruR directs the monapterin-mediated control of DcpA activity also remains to be established. An intimate relationship between PruR and DcpA is suggested by their transcriptional linkage within the same operon and the observation that their coexpression appears to potentiate the PruR-dependent stimulation of PDE activity. Regulation of DcpA via PruR could occur via several possible mechanisms, including direct binding and occlusion of the DGC domain, direct promotion of the PDE domain, or both, as well as control of proper DcpA subcellular localization. The interaction between PruR and DcpA may be through formation of a stable complex between the two proteins and a monapterin prosthetic group. Other more-complex possibilities are also possible. For example, PruR might have an as-yet-undiscovered enzymatic capability that is active only in the presence of a specific pterin cofactor, as with pterin-dependent enzymes, including phenylalanine hydroxylase ([@B58]). The enzymatic activity of PruR could directly modify DcpA or synthesize another small molecule that in turn controls DcpA activity.

Ultimately, a more detailed understanding of the PruA-PruR-DcpA pathway will result from biochemical analysis of the different regulatory components and investigation into the cellular context of its activity. Our current findings provide the first example of pterins participating in a prokaryotic signaling cascade, in this case regulating surface attachment through adhesin production in *A. tumefaciens*. Pterins are produced by diverse bacteria, and thus, it is possible that similar pterin-dependent control is widespread.

MATERIALS AND METHODS {#h3}
=====================

Reagents, media, strains, and growth conditions. {#s3.1}
------------------------------------------------

All strains and plasmids and all oligonucleotides used in this study are provided in [Tables S1 and S2](#tabS1 tabS2){ref-type="supplementary-material"} in the supplemental material, respectively. The design and verification of plasmids and engineered genetic derivatives, including site-specific mutagenesis, deletions, and allelic exchanges were performed as described in previous publications ([@B45], [@B50]) with specific details included in [Text S1](#textS1){ref-type="supplementary-material"} in the supplemental material.

Biofilm analysis and UPP adhesin assays. {#s3.2}
----------------------------------------

Biofilms of *A. tumefaciens* derivatives were cultivated in minimal medium on polyvinyl chloride (PVC) coverslips in 12-well plates, and adherent biomass was measured using crystal violet as in our prior publications ([@B45], [@B78]). Cells producing the UPP adhesin were examined using epifluorescence microscopy and the fluorescently labeled lectin af-WGA as described previously ([@B50]).

c-di-GMP measurements. {#s3.3}
----------------------

Extracts were prepared from cultures of *A. tumefaciens* and *E. coli* derivatives and analyzed using LC-MS/MS on a Quattro Premier XE mass spectrometer (Waters Corporation) coupled with an Acquity ultraperformance LC system (Waters Corporation) as described in a previous publication ([@B50]).

Extraction and analysis of pterins from *A. tumefaciens.* {#s3.4}
---------------------------------------------------------

Whole-cell extracts prepared from late-exponential-phase cultures of *A. tumefaciens* were prepared, and pterins were enriched using cation exchange chromatography. These preparations were analyzed using HPLC on a reverse-phase C~18~ column with fluorescence detection as previously described ([@B79]) and provided in [Text S1](#textS1){ref-type="supplementary-material"} in the supplemental material in more detail.

Purification and enzymatic assay of His6-PruA. {#s3.5}
----------------------------------------------

An N-terminal hexahistidinyl-tagged PruA (His6-PruA) derivative was expressed in *E. coli* and affinity purified. This preparation was tested for enzymatic activity using an H~2~MPt substrate prepared by reduction of monapterin and a dihydrofolate substrate using an assay monitoring consumption of NADPH in the reaction spectrophotometrically using extinction coefficients for the NADPH-pterin oxidation-reduction pair.

Additional details on the materials and methods used in this study are provided in [Text S1](#textS1){ref-type="supplementary-material"} in the supplemental material.

SUPPLEMENTAL MATERIAL {#sm1}
=====================
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DcpA domain alignments. Alignments performed using ClustalX multiple alignment mode and neighbor-joining (NJ) clustering algorithm. (A) Alignment of the DGC domain of DcpA to characterized DGC proteins. Residues important for catalytic function are outlined in red. (B) Alignment of the DcpA EAL domain to characterized proteins containing EAL domains. Residues important for catalytic function are outlined in red. Download
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Figure S1, PDF file, 0.1 MB
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Additional Δ*dcpA* phenotypes. (A) Congo red phenotypes of the indicated *A. tumefaciens* strains. Exponential-phase cultures were normalized to an OD~600~ of 0.5, and 5 µl of the corresponding culture was spotted onto ATGN minimal medium plates containing 100 µg/ml Congo red and 400 µM IPTG. Pictures were taken after 48 h of growth at 28°C. DGC−, DcpA variant containing catalytic site GGDEF→GGDAF mutation; PDE−, DcpA variant containing catalytic site EAL→AAL mutation. (B) Adherent bacterial biomass grown for 48 h on PVC coverslips quantified by the amount of solubilized crystal violet (CV) at *A*~600~, as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. In parallel, the OD~600~ of nonattached culture was determined to quantify planktonic culture growth, and absorbance was normalized to culture growth by calculating the *A*~600/~OD~600~ ratio. The indicated amounts of IPTG were added. Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. Download
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Figure S2, PDF file, 0.1 MB
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Intracellular c-di-GMP levels. (A) Quantification of intracellular levels of c-di-GMP in the indicated *A. tumefaciens* strains. Strains were grown to stationary phase, nucleotides were extracted, and measurements of c-di-GMP were obtained by LC-MS/MS as described in Materials and Methods. All strains were constructed in an extracellular polymeric substance (EPS)-negative strain background ([@B45]) in which the genes coding for the polysaccharides succinoglycan, cellulose, cyclic β-1-2 glucans, and curdlan (β-1-3-glucans) have been deleted. Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. Download
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Figure S3, PDF file, 0.02 MB
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PruA orthologs complement Δ*pruA* phenotypes. (A) *A. tumefaciens* pruA aligned to orthologs from other *Rhizobiales* and alphaproteobacterial species. Orthologs from *C. crescentus* CC0417, *R. pomeroyi* Spo3638, *S. meliloti* SMc00603, *Brucella melitensis* bv. *abortus* BAB1_0721, and *E. coli* folM were used. Residues important for catalytic function are outlined in red. Alignments were performed using ClustalX multiple alignment mode and NJ clustering algorithm. (B) Adherent bacterial biomass grown for 48 h on PVC coverslips was quantified by the amount of solubilized crystal violet (CV) at *A*~600~ as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. In parallel, OD~600~ of nonattached culture was determined to quantify planktonic culture growth, and absorbance was normalized to culture growth by calculating the *A*~600/~OD~600~ ratio. A mutant with no plasmid inserted is indicated (hyphen). Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. (C) Congo red phenotypes of the indicated *A. tumefaciens* strains. Cultures were normalized to an OD~600~ of 0.5, and 5 µl of corresponding culture was spotted onto ATGN minimal medium plates containing 100 µg/ml Congo red and 400 µM IPTG. The images were taken after 48 h of growth at 28°C. (D) Predicted PruA protein structure. Structure predicted using PHYRE database (<http://www.sbg.bio.ic.ac.uk/phyre2>). *Leishmania* pteridine reductase structure (PDB identifier \[ID\] 2XOX) is shown for comparison. Alpha helices and beta sheets are highlighted in green and red, respectively. The PruA catalytic tyrosine residue is indicated by a white arrow. Download
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Figure S4, PDF file, 0.3 MB
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PruA enzymatic function necessary for regulation of DcpA DGC/PDE activity. Adherent bacterial biomass grown for 48 h on PVC coverslips quantified by the amount of solubilized crystal violet (CV) at *A*~600~ as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. In parallel, the OD~600~ of nonattached culture was determined to quantify planktonic culture growth, and absorbance was normalized to culture growth by calculating the *A*~600~/OD~600~ ratio. IPTG (400 µM) was added to each strain. Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. Download
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Figure S5, PDF file, 0.01 MB
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PruR sequence and role in attachment control. (A) Several PruR homologs are missing the cysteine required for molybdopterin binding. *A. tumefaciens* pruR homologs *R. pomeroyi* Spo0162, *R. capsulatus* RCAP rcc01507, *R. sphaeroides* RSP_0086 were aligned to *yedY*, a known molybdopterin-binding protein from *E. coli*. The canonical cysteine is highlighted in red. OR, oxidoreductase; SO, sulfite oxidase. (B) PruA and DcpA are both required for effective PruR complementation. Adherent bacterial biomass grown for 48 h on PVC coverslips quantified by the amount of solubilized crystal violet (CV) at *A*~600~ as described in the legend to [Fig. 1C](#fig1){ref-type="fig"}. In parallel, the OD~600~ of nonattached culture was determined to quantify planktonic culture growth, and absorbance was normalized to culture growth by calculating the ratio *A*~600~/OD~600~ ratio. IPTG (400 µM) was added to each strain. Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. Download
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Figure S6, PDF file, 0.3 MB
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2′-*O*-methyl-5,6,7,8-tetrahydromonapterin biosynthesis and structure. (A) PruA, which does not possess a predicted methyltransferase capability, reduces 7,8-dihydromonapterin to 5,6,7,8-tetrahydromonapterin, which is then methylated by an unknown methyltransferase to generate 2′-*O*-methyl-5,6,7,8-tetrahydromonapterin. (B) Major fragment ions derived from chemically synthesized 2′-methoxymonapterin during MS/MS analysis. Collisionally induced fragments arising from 2′-*O*-methylmonapterin observed in both the pterin isolated from *A. tumefaciens* and the chemically synthesized standard. The 191 *m/z* fragment was not observed upon analysis of chemically synthesized 3′-*O*-methylmonapterin (data not shown), providing evidence that the methylation is at the 2′ position in the new pterin from *A. tumefaciens***.** (C) 2′-*O*-methylmonapterin mass spectra. MS/MS spectrum of the unknown pterin from wild-type *A. tumefaciens* cells (top) and of chemically synthesized 2′-O-methylmonapterin (bottom). Download
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